PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Presentation (August 2019)

34 slides from PhaseBio Pharmaceuticals's investor presentation, Aug 14, 2019

  1. Slide 1: Corporate Overview August 2019

    Corporate Overview August 2019 Exhibit 99.2

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)

  3. Slide 3: Company Overview

    Company Overview Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications Product Candidates PB2452 – Novel agent for immediate and sustained reversal of ticag

  4. Slide 4: A Clinical Stage, Orphan Disease-Focused Biopharmaceutical Company

    Program Indication/Therapeutic Area Pre-Clinical Phase 1 Phase 2 Phase 3 WW Commercial Rights Milestones PB2452 Reversal of Ticagrelor Antiplatelet Activity Q4 2019: Initiate Phase 2b trial Q1 2020: Initiate Phase 3 trial based on plan to pursue accelerated regulatory pathway PB1046 Pulmonary Arteri

  5. Slide 5: Corporate

    Corporate

  6. Slide 6: Recent Corporate Highlights

    Recent Corporate Highlights Announced receipt of meeting minutes from PB2452 End-of-Phase 1 meeting with FDA: August 2019 FDA agreement on development plan and Accelerated Approval regulatory path Single, non-randomized, open label Phase 3 trial in both surgical and major bleeding populations planne

  7. Slide 7: Second-Quarter 2019 Financial Highlights

    Second-Quarter 2019 Financial Highlights Operating expense: $10.2M R&D: $7.8M SG&A: $2.4M Loss from Operations: ($9.5M) Net Loss of ($9.2M) or ($0.33) per share 27.9M shares used for computing Q2 2019 net loss per share Cash and cash equivalents as of 06/30/2019: $90.3M All values in USD millions ex

  8. Slide 8: Experienced Management Team

    Experienced Management Team JONATHAN MOW Chief Executive Officer Amylin Pharmaceuticals, Corus Pharma, PathoGenesis, BMS JOHN SHARP Chief Financial Officer Ligand Pharmaceuticals, HUYA Bioscience, Sequenom, Diversa JOHN LEE, MD, PhD, FACC Chief Medical Officer Merck, BMS, Quintiles SUSAN ARNOLD, PhD

  9. Slide 9: PB2452 – Reversal Agent for Ticagrelor

    PB2452 – Reversal Agent for Ticagrelor

  10. Slide 10: PB2452 - Novel reversal agent for Brilinta (ticagrelor)

    PB2452 - Novel reversal agent for Brilinta (ticagrelor) Human monoclonal antibody fragment (Fab), delivered intravenously in the hospital Phase 1 Proof of Concept Study completed Selected for late-breaking oral presentation American College of Cardiology’s Annual Scientific Session (March 17, 2019)

  11. Slide 11: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor

    PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor ADP ADP Platelet ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation This is a reversible process with ticagrelor cycling on/off the P2Y12 receptors PB2452:ticag

  12. Slide 12: FDA has agreed that Accelerated Approval pathway is appropriate for PB2452

    FDA has agreed that Accelerated Approval pathway is the appropriate regulatory pathway for PB2452 Single, non-randomized, open label Phase 3 trial in both surgical and major bleeding populations planned to support a Biologics License Application (BLA) BLA submission for Accelerated Approval to inclu

  13. Slide 13: Positive Preliminary PB2452 Phase 2a Results

    Positive Preliminary PB2452 Phase 2a Results In June 2019, positive preliminary results from the PB2452 Phase 2a trial were disclosed via press release1 This is the first trial of PB2452 to include older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and lo

  14. Slide 14: PB2452 Granted Breakthrough Therapy Designation

    PB2452 Granted Breakthrough Therapy Designation In April 2019, PB2452 was granted Breakthrough Therapy designation by FDA Designation supported by Phase 1 trial results, which were recently published in the New England Journal of Medicine1 Breakthrough Therapy designation may be granted by FDA when

  15. Slide 15: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects

    PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Selected as late-breaking oral presentation during featured clinical research session at the American College of Cardiology’s Annual Scientific Session – March 17, 20191 Simultaneously published in the New England Journal of Medicine2 https:/

  16. Slide 16: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects

    PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Randomized, double-blind, placebo-controlled, single ascending dose (SAD), sequential group study (n=64) 3:1 randomization, PB2452-Placebo Higher-dose cohorts pre-treated with ticagrelor After 48 hours of ticagrelor, platelet aggregation was

  17. Slide 17: Phase 1 Cohort Dosing Regimens

    Cohort Ticagrelor Pretreatment PB2452 IV regimen Volunteers Active:Placebo 1 None 0.1 g 30 min 3A:1P 2 None 0.3 g 30 min 3A:1P 3 None 1 g 30 min 3A:1P 4 180 mg PO + 90 mg BID x 2 days 1 g 30 min 6A:2P 5 180 mg PO + 90 mg BID x 2 days 3 g 30 min 6A:2P 6 180 mg PO + 90 mg BID x 2 days 9 g 30 min 6A:2P

  18. Slide 18: Normalized Platelet Function After Ticagrelor Reversal

    PRU= Platelet Reactivity Units Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med 2019;Mar 17:[Epub ahead of print]. Presented by Dr. Deepak L. Bhatt at the American College of Cardiology Annual Scientific Session (ACC 2019), New Orlea

  19. Slide 19: Platelet Aggregation with AA and TRAP

    %Platelet aggregation by AA Nominal Time (h) Platelet Aggregation with AA and TRAP Mean platelet aggregation by LTA using AA (top) or TRAP (bottom) as agonist %Platelet aggregation by TRAP Nominal Time (h) Arachidonic acid (AA) Thrombin receptor activating peptide (TRAP) No platelet rebound effect o

  20. Slide 20: Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of TEAEs 3 27 Number of volunteers with at Least 1 TEAE 2 (12.5) 17 (35.4) Infusion site bruising 0 4 (8.3) Medical device site reaction 0 3 (6.3) Infusion site extravasation 0 2 (4.2) Vess

  21. Slide 21: Clinical Studies BLA Enabling Data

    Clinical Studies BLA enabling data Clinical Trial Timelines Phase 2a testing additional reversal regimen to cover 180 mg BID (2x recommended dose) in healthy older and elderly subjects on DAPT Trial will be completed Q4 2019, not required to finish prior to Phase 2b Phase 2b expected to start Q4 201

  22. Slide 22: Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 Approval

    Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval Brilinta/Brilique sales in 2018 were $1.32B and growing (+22% Y/Y) Patient growth drives Y/Y revenue growth in all regions: EU (+18%), US (+16%), Emerging Markets (+46%) In February 2019, Brilinta Phase III THEMIS1 trial met pri

  23. Slide 23: PB2452 Program Summary and Next Steps

    PB2452 Program Summary and Next Steps Product profile: Immediate and sustained reversal of ticagrelor antiplatelet effects Major bleeding and urgent surgical scenarios require immediate and sustained reversal Duration of reversal dependent on infusion length Clinically important immediate and sustai

  24. Slide 24: Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

    Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

  25. Slide 25: Prolonged Circulating Half-Life

    PROLONGED CIRCULATING HALF-LIFE Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active Moiety “Biopolymer” n UP TO 200x INCREASE IN ½ LIFE Proprietary Elastin-Like Polypeptide (ELP) Technology Growth Engine for PhaseBio Preclinical Pipeline ↑ Temperature COACERVA

  26. Slide 26: ELP: A Highly Flexible Technology for Modulating Pharmacokinetics

    ELP: A Highly Flexible Technology for Modulating Pharmacokinetics VERSATILE: MANY ACTIVE MOIETIES POSSIBLE Peptides or proteins can be genetically fused to N- or C-terminus1, or both. Chemical conjugation to small molecules or peptides LOW COST MANUFACTURING Can be produced in E.coli, yeast or mamma

  27. Slide 27: PB1046 - Once Weekly VIP Analog for Pulmonary Arterial Hypertension

    PB1046 - Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension

  28. Slide 28: High Unmet Need in an Orphan Disease

    High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) High unmet need for novel disease-modifying PAH therapies for greater efficacy All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways Patients inevitab

  29. Slide 29: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug

    PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug PRECLINICAL STUDIES Support Clinical Development for: Pulmonary Arterial Hypertension DMD Cardiomyopathy Heart Failure (Chemotherapy-Induced HF or HFpEF) Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR Potent vasodilator Anti-inflamm

  30. Slide 30: Phase 1 Studies Completed

    PHASE 1 Studies Completed PAH PHASE 2 Studies Well tolerated for a week over broad range of exposure; no drug-related SAEs Prolonged PK/PD profile over 1 week VIP activity confirmed (Systolic and Diastolic BP lowering) Well tolerated across dose range; no drug-related SAEs Replicated PK/PD from SAD

  31. Slide 31: PB1046 Single Ascending Dose Study

    PB1046 Single Ascending Dose Study PK and PD Support Once-Weekly SC Administration Single subcutaneous injections in hypertensive patients washed off medications Well tolerated, week-long PK, dose-dependent VIP activity observed Supports weekly SC dosing in multi-dose studies Serum Concentration PB1

  32. Slide 32: PB1046 Multiple Ascending Dose Study

    PB1046 Multiple Ascending Dose Study Multi-Dose Safety and PK/PD Confirmed in HFrEF Patients MAD in HFrEF completed 4Q2017 Weekly SC injections x 4 weeks in 29 HF patients maintained on SOC meds Well tolerated in a sick patient population on multiple vasoactive medications Prolonged PK profile repli

  33. Slide 33: PB1046 Phase 2b PAH Study Actively Recruiting

    PB1046 Phase 2b PAH Study Actively Recruiting PAH WHO functional class II/III subjects on two drug oral SOC therapy 16 week randomized, double-blinded, controlled study with extension Primary endpoints: Pulmonary vascular resistance (PVR) via RHC, 6MWD, safety Designed to support placebo-controlled

  34. Slide 34: Slide 34

PhaseBio Pharmaceuticals — Investor Presentation (August 2019) on 6ix